Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

METformin in DIastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design : MET-DIME trial.

Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, Sampaio F, Gama V, Leite-Moreira AF.

Cardiovasc Drugs Ther. 2014 Apr;28(2):191-6. doi: 10.1007/s10557-014-6512-2.

PMID:
24515256
2.

The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction.

Al Ali L, Hartman MT, Lexis CP, Hummel YM, Lipsic E, van Melle JP, van Veldhuisen DJ, Voors AA, van der Horst IC, van der Harst P.

PLoS One. 2016 Dec 15;11(12):e0168340. doi: 10.1371/journal.pone.0168340. eCollection 2016.

3.

Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial.

Lexis CP, van der Horst IC, Lipsic E, van der Harst P, van der Horst-Schrivers AN, Wolffenbuttel BH, de Boer RA, van Rossum AC, van Veldhuisen DJ, de Smet BJ; GIPS-III Investigators.

Cardiovasc Drugs Ther. 2012 Oct;26(5):417-26. doi: 10.1007/s10557-012-6413-1.

4.

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.

Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo-DHF Investigators.

JAMA. 2013 Feb 27;309(8):781-91. doi: 10.1001/jama.2013.905.

PMID:
23443441
5.

Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.

Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, Caporotondi A, Mortara A, Pinna GD, Cobelli F.

Am Heart J. 2000 Apr;139(4):596-608.

PMID:
10740140
6.

[Prognostic relevance of left ventricular diastolic function parameters in dilated cardiomyopathy].

Schannwell CM, Schoebel FC, Marx R, Plehn G, Leschke M, Strauer BE.

Z Kardiol. 2001 Apr;90(4):269-79. German.

PMID:
11381575
7.

Aortic stiffness is an independent determinant of left ventricular diastolic dysfunction in metabolic syndrome patients.

Solovjova S, Ryliškytė L, Čelutkienė J, Badarienė J, Navickas R, Puronaitė R, Bieliauskaitė G, Skiauterytė E, Lisaitė G, Laucevičius A.

Blood Press. 2016;25(1):11-20. doi: 10.3109/08037051.2016.1093334.

PMID:
26556678
8.

Is left ventricular diastolic dysfunction independent from presence of hypertension in metabolic syndrome? An echocardiographic study.

Aksoy S, Durmuş G, Özcan S, Toprak E, Gurkan U, Oz D, Canga Y, Karatas B, Duman D.

J Cardiol. 2014 Sep;64(3):194-8. doi: 10.1016/j.jjcc.2014.01.002. Epub 2014 Feb 10.

9.

[Effect of captopril on left ventricular diastolic dysfunction in young insulin dependent diabetic patients with microalbuminuria].

Fernández-Fúnez A, Cabrera Solé R, Hernández A, Martínez V, Solera J.

Med Clin (Barc). 2002 Mar 16;118(9):321-6. Spanish.

PMID:
11900699
10.
11.

Impact of sex on the heart's metabolic and functional responses to diabetic therapies.

Lyons MR, Peterson LR, McGill JB, Herrero P, Coggan AR, Saeed IM, Recklein C, Schechtman KB, Gropler RJ.

Am J Physiol Heart Circ Physiol. 2013 Dec 1;305(11):H1584-91. doi: 10.1152/ajpheart.00420.2013. Epub 2013 Sep 16.

12.

Selective Heart Rate Reduction Improves Metabolic Syndrome-related Left Ventricular Diastolic Dysfunction.

Merabet N, Fang Y, Nicol L, Monteil C, Rémy-Jouet I, Henry JP, Wecker D, Le Bouter-Banon S, Roussel J, Richard V, Thuillez C, Mulder P.

J Cardiovasc Pharmacol. 2015 Oct;66(4):399-408. doi: 10.1097/FJC.0000000000000294.

PMID:
26222991
14.

Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension.

Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, Coelho OR, Yugar-Toledo JC, Fontana V, Calhoun D, Moreno H.

Eur J Clin Pharmacol. 2014 Feb;70(2):147-54. doi: 10.1007/s00228-013-1611-8. Epub 2013 Nov 24.

PMID:
24271647
15.

Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy.

Leung M, Wong VW, Heritier S, Mihailidou AS, Leung DY.

Cardiovasc Diabetol. 2013 Oct 1;12:139. doi: 10.1186/1475-2840-12-139.

17.

HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.

Hermida N, Markl A, Hamelet J, Van Assche T, Vanderper A, Herijgers P, van Bilsen M, Hilfiker-Kleiner D, Noppe G, Beauloye C, Horman S, Balligand JL.

Cardiovasc Res. 2013 Jul 1;99(1):44-54. doi: 10.1093/cvr/cvt070. Epub 2013 Mar 29.

PMID:
23542580
18.

Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction.

Badano LP, Albanese MC, De Biaggio P, Rozbowsky P, Miani D, Fresco C, Fioretti PM.

J Am Soc Echocardiogr. 2004 Mar;17(3):253-61.

PMID:
14981424
19.

Myocardial dysfunction in pediatric septic shock.

Raj S, Killinger JS, Gonzalez JA, Lopez L.

J Pediatr. 2014 Jan;164(1):72-77.e2. doi: 10.1016/j.jpeds.2013.09.027. Epub 2013 Oct 18.

PMID:
24144393
20.

Determinants of subclinical diabetic heart disease.

Fang ZY, Schull-Meade R, Downey M, Prins J, Marwick TH.

Diabetologia. 2005 Feb;48(2):394-402. Epub 2005 Jan 8.

PMID:
15645206

Supplemental Content

Support Center